{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:53:02Z","timestamp":1770231182115,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007467","name":"Keio University School of Medicine Graduate School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.resinv.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:43:37Z","timestamp":1751618617000},"page":"829-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-32\u2013expressing CD4+ T cells are a potentially pathogenic subset in systemic sclerosis with interstitial lung disease"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3100-9011","authenticated-orcid":false,"given":"Sho","family":"Ishigaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.06.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.resinv.2025.06.008_bib2","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.resinv.2025.06.008_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.resinv.2025.06.008_bib6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8 Nazzareno","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.resinv.2025.06.008_bib7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","article-title":"Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib","volume":"78","author":"Ricard","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2025.06.008_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156534","article-title":"Th17\/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH","volume":"176","author":"Seki","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.resinv.2025.06.008_bib11","doi-asserted-by":"crossref","first-page":"E2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","author":"Hashimoto-Kataoka","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2025.06.008_bib12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","article-title":"Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease","volume":"78","author":"Valenzi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2025.06.008_bib13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41467-020-15647-5","article-title":"Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis","volume":"11","author":"Tsukui","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2025.06.008_bib14","article-title":"Osteopontin links myeloid activation and disease progression in systemic sclerosis","volume":"1","author":"Gao","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111697","article-title":"Systematic single-cell pathway analysis to characterize early T cell activation","volume":"41","author":"Bibby","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.resinv.2025.06.008_bib16","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.resinv.2025.06.008_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13073-020-00779-6","article-title":"Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci","volume":"12","author":"Li","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.resinv.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1136\/annrheumdis-2018-214885","article-title":"Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell","volume":"78","author":"Takeshita","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2025.06.008_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/bioinformatics\/btz854","article-title":"RaNA-Seq: interactive RNA-Seq analysis from FASTQ files to functional analysis","volume":"36","author":"Prieto","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.resinv.2025.06.008_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.resinv.2025.06.008_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.humimm.2021.05.002","article-title":"IL32: the multifaceted and unconventional cytokine","volume":"82","author":"Gautam","year":"2021","journal-title":"Hum Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib23","first-page":"131","article-title":"Interleukin-32: a cytokine and inducer of TNFalpha","volume":"22","author":"Kim","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.resinv.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1189\/jlb.4RU0416-175RR","article-title":"Interleukin 32: a novel player in the control of infectious diseases","volume":"101","author":"Ribeiro-Dias","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.resinv.2025.06.008_bib25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2010.01.016","article-title":"IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis","volume":"125","author":"Meyer","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12967-022-03375-x","article-title":"IL-32 promotes the occurrence of atopic dermatitis by activating the JAK1\/microRNA-155 axis","volume":"20","author":"Chang","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.200804-646OC","article-title":"IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease","volume":"178","author":"Calabrese","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/ar4089","article-title":"IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis","volume":"14","author":"Moon","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2025.06.008_bib29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2249.2007.03439.x","article-title":"Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease","volume":"149","author":"Shioya","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2017.07.005","article-title":"Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases","volume":"264","author":"Damen","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.resinv.2025.06.008_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4049\/jimmunol.1601045","article-title":"IL-10 receptor signaling is essential for TR1 cell function in vivo","volume":"198","author":"Brockmann","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.20102149","article-title":"Memory\/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology","volume":"208","author":"Kamanaka","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2025.06.008_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188750","article-title":"Under the influence: environmental factors as modulators of neuroinflammation through the IL-10\/IL-10R axis","volume":"14","author":"Bugbee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fimmu.2018.00455","article-title":"Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses","volume":"9","author":"Sch\u00fclke","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.02.025","article-title":"Interleukin 32, inflammation and cancer","volume":"174","author":"Hong","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.resinv.2025.06.008_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib37","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.06.008_bib38","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1093\/rheumatology\/keac031","article-title":"Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis","volume":"61","author":"Kobayashi","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2025.06.008_bib39","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1073\/pnas.0511206103","article-title":"Proteinase 3 is an IL-32 binding protein","volume":"103","author":"Novick","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2025.06.008_bib40","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1038\/srep02960","article-title":"IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis","volume":"3","author":"Nakayama","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2025.06.008_bib41","doi-asserted-by":"crossref","first-page":"35556","DOI":"10.1074\/jbc.M112.400911","article-title":"Intracellular interaction of interleukin (IL)-32\u03b1 with protein kinase C\u03b5 (PKC\u03b5) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells","volume":"287","author":"Kang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2025.06.008_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-020-02218-8","article-title":"Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension","volume":"22","author":"Di Benedetto","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:57:23Z","timestamp":1762606643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2212534525000887"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.06.008","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-32\u2013expressing CD4+ T cells are a potentially pathogenic subset in systemic sclerosis with interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}